Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may have been limited published data and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source.
Daivonex (Aust Prescr 2001;24:158)
There was a typographical error in the New Formulations section of New drugs, regarding calcipotriol scalp solution (CSL). The brand name is Daivonex, not Diavonex.
